Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Harvard Clinical Research Institute (HCRI) has expanded its DAPT Study into seven countries in the European Union (EU). Enrollment has been commenced at multiple centers across the EU and will include participation in the Czech Republic, France, Germany, Hungary, Poland, Romania and the UK.
Subscribe to our email newsletter
The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.
The large-scale public health study is expected to bring clarity to the global medical community regarding the benefits of 12 versus 30 months of dual antiplatelet therapy in patients receiving drug-eluting stents to address coronary artery lesions.
Laura Mauri, principal investigator of the DAPT Study and chief scientific officer of HCRI, said: “The expansion of the DAPT Study into the EU is an important milestone in support of our goal of enrolling over 20,000 subjects and obtaining a diversity of data that reflects real-world clinical practice.”
Gabriel Steg, DAPT national coordinator for France, DAPT executive committee member, and an interventional cardiologist at Hospital Bichat in Paris, said: “The DAPT Study addresses a critical gap in current scientific evidence. This international study will help understand the benefits and the risks associated with prolonged dual antiplatelet therapy beyond one year after stenting.”